Estrogen Receptor-positive Breast Cancer
Oncology
2
Pipeline Programs
1
Companies
2
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
U
FULVESTRANTApproved
fulvestrant
Unknown CompanyEstrogen Receptor Antagonist [EPC]intramuscular2021
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Alliance Pharmaceuticalsfulvestrant
Alliance Pharmaceuticalsfulvestrant
Clinical Trials (2)
Total enrollment: 1,553 patients across 2 trials
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Start: Feb 2014Est. completion: Apr 20271,473 patients
Phase 3Active Not Recruiting
ICI 182780 in Treating Women With Metastatic Breast Cancer
Start: May 2001Est. completion: Aug 200880 patients
Phase 2Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
32m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
32m ago
Office Administrator
SystImmune
32m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
43m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
46m ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
46m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space